[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mature-b-cell-neoplasm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mature-b-cell-neoplasm":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,68],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":52,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":67},"100481055","phase-1-study-of-sgr-1505-in-mature-b-cell-neoplasms-100481055",false,"NCT05544019","Study of SGR-1505 in Mature B-Cell Neoplasms","A Phase 1, Open-Label, Multicenter, Dose Escalation Study of SGR-1505 as Monotherapy in Subjects With Mature B-Cell Malignancies","Inclusion Criteria:\n\n* Subject must have a history of histologically or cytologically confirmed mature B-cell malignancy.\n* Subject must have measurable or detectable disease according to the applicable disease-specific classification system and meet criteria for initiation of treatment.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Life expectancy ≥ 12 weeks.\n\nExclusion Criteria:\n\n* The subject is in need of immediate cytoreductive therapy (unless the patient has no remaining treatment choice with potential benefit).\n* Subject has previous invasive malignancy in the last 2 years.\n* Subject has a known allergy to SGR-1505 or excipients of SGR-1505.\n* Subject has symptomatic or active CNS involvement of disease.\n* Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding that would place the participant at increased risk to the use of an investigational drug.","ALL","18 Years",{"count":19,"type":20},98,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and\u002For recommended dose (RD) of SGR-1505.",[26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51],"Mature B-Cell Neoplasm","Non Hodgkin Lymphoma","DLBCL","Waldenstrom Macroglobulinemia","MALT Lymphoma","Follicular Lymphoma","Pediatric-Type Follicular Lymphoma","IRF4 Gene Rearrangement","EBV-Positive DLBCL, Nos","Burkitt Lymphoma","Plasmablastic Lymphoma","High-grade B-cell Lymphoma","Primary Cutaneous Follicle Center Lymphoma","Primary Effusion Lymphoma","Mantle Cell Lymphoma","DLBCL Germinal Center B-Cell Type","Primary Mediastinal Large B Cell Lymphoma","T-Cell\u002FHistiocyte Rich Lymphoma","ALK-Positive Large B-Cell Lymphoma","Primary Cutaneous Diffuse Large B-Cell Lymphoma","Splenic Marginal Zone Lymphoma","Chronic Lymphocytic Leukemia","Nodal Marginal Zone Lymphoma","HHV8-Positive DLBCL, Nos","Lymphoplasmacytic Lymphoma","Duodenal-Type Follicular Lymphoma",[53,54,29],"MALT1","NF-kB","RECRUITING","2026-02-11",{"date":58,"type":59},"2026-02-13","ACTUAL",{"date":61,"type":59},"2023-04-10",{"date":63,"type":20},"2027-11",{"name":65,"class":66},"Schrödinger, Inc.","INDUSTRY",36,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":77,"phases":4,"briefSummary":78,"conditions":79,"keywords":80,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":95},"100307294","liquid-biopsy-in-mature-b-cell-tumors-100307294","NCT03280394","Liquid Biopsy in Mature B-cell Tumors","Prospective, Observational, Multi-centred, Non-interventional Research Project on Plasma Cell Free DNA Genotyping as a Tool to Inform Mature B-cell Tumor Management","Inclusion Criteria:\n\n* Male or female adults 18 years or older\n* Documented diagnosis of mature B-cell tumor according to WHO 2008 criteria\n* Willing and able to comply with scheduled study procedures\n* Evidence of a signed informed consent",{"count":76,"type":20},444,"OBSERVATIONAL","The study aims at assessing whether cell free DNA genotyping can improve the accuracy of early prediction of cure in mature B-cell tumor patients and whether it represents an accessible source of tumor DNA for the sensitive identification of genetic biomarkers that refine the diagnostic workup, stratify prognosis and identify the emergence of drug-resistance mutations during treatment.",[26],[81,82,83,31,40,84],"Liquid biopsy","Classical Hodgkin Lymphoma","Diffuse Large B Cell Lymphoma","Mutations","2023-10-31",{"date":87,"type":59},"2023-11-01",{"date":89,"type":59},"2017-09-01",{"date":91,"type":20},"2027-12-31",{"name":93,"class":94},"Oncology Institute of Southern Switzerland","OTHER",1]